Immunotherapy against Invasive Mold Infections

Antachopoulos, Charalampos; Katragkou, Aspasia; Roilides, Emmanuel

doi:10.2217/imt.11.159

Cited by 13 publications

(3 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…). The interest in this approach dramatically increased when recombinant haematopoietic growth factors, such as the granulocyte colony‐stimulating factor (G‐CSF), became available as they markedly enhance the yield of leucocytes from healthy donors . Common adverse events reported in up to 20% of granulocyte transfusions include fever and chills, and pulmonary reactions may also occur, presenting as acute respiratory distress syndrome .…”

Section: Granulocytesmentioning

confidence: 99%

Immunotherapeutic strategies against mucormycosis in haematopoietic stem cell transplantation

Schmidt

Tramsen

Schneider

et al. 2014

Mycoses

View full text Add to dashboard Cite

SummaryMucormycoses remain a serious complication in patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). In these patients, mortality rates of mucormycosis reach up to 90%, which is due, at least in part, to the severe and prolonged immunosuppression after transplantation. Although prolonged neutropaenia is one of the most important risk factors for mucormycosis, other cell populations, such as CD4 + T cells may also provide critical defence mechanisms against this infection. The management of mucormycosis includes antifungal therapy, surgery and, most importantly, the control of the underlying predisposing conditions, such as the correction of an impaired immune system. Here, we review the current data of granulocytes, antifungal T cells and natural killer cells regarding their activity against mucormycetes and regarding a potential immunotherapeutic approach. It is hoped that further animal studies and clinical trials assessing immunotherapeutic strategies will ultimately improve the poor prognosis of allogeneic HSCT recipients suffering from mucormycosis.

show abstract

Section: Granulocytesmentioning

confidence: 99%

Immunotherapeutic strategies against mucormycosis in haematopoietic stem cell transplantation

Schmidt

Tramsen

Schneider

et al. 2014

Mycoses

View full text Add to dashboard Cite

show abstract

“…and Alternaria sp. cause significant morbidity and mortality in immunocompromised patients with hematological malignancies, recipients of hematopoietic stem cell transplants and those with chronic granulomatous disease (Antachopoulos et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Identification study some virulence factors of invasive mold infections isolated from patients undergoing chemotherapy in Tikrit teaching Hospital

Mezher

Ra²,

Bandar³

2015

Egyptian Academic Journal of Biological Sciences, G. Microbiolo

View full text Add to dashboard Cite

“…These in vitro and in vivo results may represent a hope for allogeneic hematopoietic stem cell transplantation recipients with invasive fungal infection. However, there is no sufficient clinical evidence to formulate recommendations to use this approach in systemic zygomycosis [109]. …”

Section: Epidemiologymentioning

confidence: 99%

Biology, systematics, and clinical manifestations of Zygomycota infections

Muszewska

Pawłowska

Krzyściak

2014

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Fungi cause opportunistic, nosocomial, and community-acquired infections. Among fungal infections (mycoses) zygomycoses are exceptionally severe, with a mortality rate exceeding 50 %. Immunocompromised hosts, transplant recipients, and diabetic patients with uncontrolled keto-acidosis and high iron serum levels are at risk. Zygomycota are capable of infecting hosts immune to other filamentous fungi. The infection often follows a progressive pattern, with angioinvasion and metastases. Moreover, current antifungal therapy frequently has an unfavorable outcome. Zygomycota are resistant to some of the routinely used antifungals, among them azoles (except posaconazole) and echinocandins. The typical treatment consists of surgical debridement of the infected tissues accompanied by amphotericin B administration. The latter has strong nephrotoxic side effects, which make it unsuitable for prophylaxis. Delayed administration of amphotericin and excision of mycelium-containing tissues worsens survival prognoses. More than 30 species of Zygomycota are involved in human infections, among them Mucorales is the most abundant. Prognosis and treatment suggestions differ for each species, which makes fast and reliable diagnosis essential. Serum sample PCR-based identification often gives false-negative results; culture-based identification is time-consuming and not always feasible. With the dawn of Zygomycota sequencing projects significant advancement is expected, as in the case of treatment of Ascomycota infections.Electronic supplementary materialThe online version of this article (doi:10.1007/s10096-014-2076-0) contains supplementary material, which is available to authorized users.

show abstract

Immunotherapy against Invasive Mold Infections

Cited by 13 publications

References 119 publications

Immunotherapeutic strategies against mucormycosis in haematopoietic stem cell transplantation

Immunotherapeutic strategies against mucormycosis in haematopoietic stem cell transplantation

Identification study some virulence factors of invasive mold infections isolated from patients undergoing chemotherapy in Tikrit teaching Hospital

Biology, systematics, and clinical manifestations of Zygomycota infections

Contact Info

Product

Resources

About